<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03429075</url>
  </required_header>
  <id_info>
    <org_study_id>17HH3790</org_study_id>
    <secondary_id>2017-000219-18</secondary_id>
    <nct_id>NCT03429075</nct_id>
  </id_info>
  <brief_title>Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms</brief_title>
  <acronym>Psilodep-RCT</acronym>
  <official_title>Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alexander Mosely Charitable Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised double-blind clinical trial. The aim is to compare the efficacy and
      mechanisms of action of psilocybin, the primary psychoactive substance in 'magic mushrooms',
      with the SSRI (selective serotonin reuptake inhibitor) escitalopram for major depressive
      disorder (MDD).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 7, 2019</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>functional magnetic resonance imaging (fMRI)</measure>
    <time_frame>Baseline measure vs 6 weeks post 1st psilocybin dosing</time_frame>
    <description>Change in blood oxygen level dependent (BOLD) signal during fMRI in response to emotional faces during an emotional faces paradigm done inside the fMRI scanner.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptomatology (QIDS-SR16)</measure>
    <time_frame>Baseline vs 6 weeks post 1st psilocybin dosing</time_frame>
    <description>Change in QIDS-SR16 (self-rated measure of depressive symptoms). Scale is composed of 16 items that correlate with the 9 DSM-IV symptom criteria for depression. Each response is graded 0-4 (none-severe symptoms). Questions 1-4 concern sleep disturbances, Question 5 addresses sad mood, Questions 6-9 appetite/weight, Question 10 concentration, Question 11 self-criticism, Question 12 suicidal ideation, Question 13 interest, Q14 energy/fatigue and Questions 15-16 psychomotor agitation/retardation. All questions that address the same topic are grouped and only the highest score from each group is summed up together with the other questions in order to produce a total score. Scores can range from 0-27 and depression severity is graded based on the total score in the following way: 1-5 = No depression 6-10 = Mild depression 11-15 = Moderate depression 16-20 = Severe depression 21-27 = Very severe depression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Depressive Disorder, Major</condition>
  <arm_group>
    <arm_group_label>Psilocybin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Psilocybin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escitalopram</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive Escitalopram</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Psilocybin + Placebo</intervention_name>
    <description>Multiple dosing days psilocybin vs 6 weeks of daily placebo</description>
    <arm_group_label>Psilocybin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Psilocybin + Escitalopram</intervention_name>
    <description>Multiple dosing days psilocybin vs 6 weeks of daily escitalopram</description>
    <arm_group_label>Escitalopram</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Major depressive disorder (DSM-IV)

          2. Depression of moderate to severe degree (17+ on the 21-item HAM-D).

          3. No MRI contraindications

          4. No SSRI contraindications

          5. Has a GP (general practitioner) or other mental healthcare professional who can
             confirm diagnosis

          6. 18-80 years of age

          7. Males and females

          8. Sufficiently competent with English language

        Key exclusion criteria:

          1. Current or previously diagnosed psychotic disorder

          2. Immediate family member with a diagnosed psychotic disorder

          3. Medically significant condition rendering unsuitability for the study (e.g., diabetes,
             epilepsy, severe cardiovascular disease, hepatic or renal failure e.g. CLRC &lt; 30
             ml/min etc.)

          4. History of serious suicide attempts requiring hospitalisation.

          5. Significant history of mania (determined by study psychiatrist and medical records)

          6. Psychiatric condition judged to be incompatible with establishment of rapport with
             therapy team and/or safe exposure to psilocybin, e.g. borderline personality disorder

          7. Blood or needle phobia

          8. Positive pregnancy test at screening or during the study, women who are planning a
             pregnancy and/or women who are nursing/breastfeeding.

          9. Participants who do not agree to use an acceptable contraceptive method throughout
             their participation in study.

         10. Current drug or alcohol dependence

         11. No email access

         12. Use of contraindicated medication

         13. Patients presenting with abnormal QT interval prolongation at screening or with a
             history of this (QTc at screening above 440ms for men and above 470ms for women)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J Nutt, Medicine</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Imperial College Hammersmith campus</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA, Forbes B, Feilding A, Taylor D, Curran HV, Nutt DJ. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl). 2018 Feb;235(2):399-408. doi: 10.1007/s00213-017-4771-x. Epub 2017 Nov 8.</citation>
    <PMID>29119217</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 6, 2017</study_first_submitted>
  <study_first_submitted_qc>February 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2018</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>mdd</keyword>
  <keyword>major depression</keyword>
  <keyword>major depressive disorder</keyword>
  <keyword>unipolar depression</keyword>
  <keyword>psilocybin</keyword>
  <keyword>psychedelics</keyword>
  <keyword>psychedelic</keyword>
  <keyword>escitalopram</keyword>
  <keyword>ssri</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Psilocybin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

